e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 1, 2009
Ardea Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction
of incorporation)
|
|
1-33734
(Commission
File Number)
|
|
94-3200380
(IRS Employer
Identification No.) |
| |
|
|
4939 Directors Place
San Diego, California
(Address of principal executive offices)
|
|
92121
(Zip Code) |
Registrant’s telephone number, including area code: (858) 652-6500
Not applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
TABLE OF CONTENTS
|
|
|
| Item 7.01. |
|
Regulation FD Disclosure |
A copy of presentation materials describing the business of Ardea Biosciences, Inc. (the
“Company”), all or a part of which may be used by the Company in investor or scientific
presentations from time to time, is furnished as Exhibit 99.1 hereto. These materials include
updates to information previously furnished by the Company regarding the Company’s research and
development programs, including information relating to expected research and development
milestones. The Company does not intend to furnish any update of these presentation materials in
the future. The fact that these updated presentation materials are being furnished should not be
deemed an admission as to the materiality of any information contained in the materials.
The Company has recently received and publicly announced certain clinical data related to its
products. A copy of the press release announcing the data is furnished as Exhibit 99.2 to this Form
8-K and is incorporated herein by reference in its entirety.
The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, except as shall be
expressly set forth by specific reference in such filing.
|
|
|
| Item 9.01. |
|
Financial Statements and Exhibits. |
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
| |
|
|
|
|
| Exhibit |
|
|
| Number |
|
Document Description |
| |
99.1 |
|
|
Ardea Biosciences, Inc. presentation materials dated as
of December 1, 2009, and to be used from time to time
thereafter. |
| |
99.2 |
|
|
Press release dated December 1, 2009. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
|
|
|
|
| |
ARDEA BIOSCIENCES, INC.
|
|
| Date: December 1, 2009 |
/s/ JOHN W. BECK
|
|
| |
John W. Beck |
|
| |
Chief Financial Officer |
|
| |
EXHIBIT LIST
| |
|
|
|
|
| Exhibit |
|
|
| Number |
|
Document Description |
| |
99.1 |
|
|
Ardea Biosciences, Inc. presentation materials dated as of December 1, 2009, and to be used from time to time thereafter. |
| |
99.2 |
|
|
Press release dated December 1, 2009. |